As healthcare providers, we are dedicated to patient care and safety. A critical aspect of this is preventing hospital-acquired infections (HAIs), which can lead to significant morbidity, mortality, and financial burden on the healthcare system.
HAIs are infections patients acquire while receiving treatment for other conditions. They affect approximately 1 in 31 hospital patients in the United States. The most common types include pneumonia, surgical site infections, gastrointestinal infections, urinary tract infections, and bloodstream infections.
Prevention strategies are multifaceted and should be tailored to the specific type of HAI. General strategies include hand hygiene, use of personal protective equipment, sterilization of equipment, and environmental cleaning. Adherence to these practices is crucial in reducing the incidence of HAIs.
Treatment involves identifying the causative organism through microbiological testing and providing appropriate antimicrobial therapy. In some cases, surgical intervention may be necessary to remove infected tissue or devices. It is essential to monitor patients closely for signs of infection and intervene promptly.
Antimicrobial stewardship programs play a key role in preventing the emergence of antimicrobial resistance, a significant concern with HAIs. These programs promote the appropriate use of antimicrobials, including selection, dosing, route, and duration of therapy.
Preventing and managing HAIs is a critical aspect of patient care. It requires a comprehensive approach that includes adherence to infection prevention practices, prompt identification and treatment of infections, and effective antimicrobial stewardship. By understanding and addressing these aspects, we can significantly reduce the burden of HAIs and improve patient outcomes.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation